B-cell centrality dictates therapeutic efficacy across autoimmune diseases: a systematic review. (PubMed, Front Immunol) - Sep 26, 2026 - "We observed that autoantibody-mediated diseases pemphigus vulgaris and myasthenia gravis had the most superior and durable immune response to B-cell depletion by rituximab and inebilizumab, respectively...Combination therapy using belimumab and rituximab resulted in a significantly better clinical outcome than monotherapy in Sjögren's syndrome...The success of B-cell therapeutics appears to align with B-cell contribution, disease biology, and the depth of B-cell targeting in autoimmune conditions. Precision targeting is needed to effectively combat autoimmune diseases."
Journal • Review • CNS Disorders • Dermatology • Immunology • Inflammatory Arthritis • Myasthenia Gravis • Pemphigus Vulgaris • Rheumatoid Arthritis • Rheumatology • Scleroderma • Sjogren's Syndrome • Systemic Sclerosis
|
|
Alpana Sharma; Harsh Goel; Taruna Madan; Vishakha Hooda
|